Barclays analyst Carter Gould lowered the firm’s price target on Amgen to $227 from $230 and keeps an Underweight rating on the shares ahead of the Q1 results. The analyst is below Street estimates on revenue and earnings, expecting "notable misses" on Otezla, Prolia, and Amgevita.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on AMGN:
- Editas Medicine appoints Reeve as Chair of Board, Levy as new director
- InflaRx upgraded to Buy at Guggenheim after Gohibic gets COVID EUA
- Early notable gainers among liquid option names on April 5th
- Viridian Therapeutics initiated with a Buy at Stifel
- Nvidia unveils language models, generative AI service to help Life Sciences R&D
